Tempus AI, Inc. Class A Common Stock (TEM)TEM

Upturn Advisory Summary

Analysis of Past Upturns

Type: Stock	Upturn Star Rating​	Today’s Advisory: PASS
Profit: -11.46%	Upturn Advisory Performance 1	Avg. Invested days: 16
Profits based on simulation	Stock Returns Performance 1	Last Close 09/18/2024

Type: Stock	Today’s Advisory: PASS
Profit: -11.46%	Avg. Invested days: 16
Upturn Star Rating​	Stock Returns Performance 1
Profits based on simulation Last Close 09/18/2024	Upturn Advisory Performance 1

Key Highlights

Earnings Date

Valuation

Analyst Ratings

About Tempus AI, Inc. Class A Common Stock

Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a collaboration with united therapeutics to study use of AI to detect patients at risk for pulmonary hypertension. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc in January 2023. Tempus AI, Inc was incorporated in 2015 and is headquartered in Chicago, Illinois.